



*fondazione per la ricerca
sulla fibrosi cistica - onlus*

Italian Cystic Fibrosis Research Foundation

VII CONVENTION D'AUTUNNO DEI RICERCATORI IN FIBROSI CISTICA

Verona, November 27-28, 2009

Centro Culturale "G. Marani" (Ospedale Maggiore, P. le Stefani 1)

Advanced Programme 4 (updated Nov. 09 2009)

Friday November 27 (Aula Incontri - Anfiteatro)

9.45-10.00 *Meeting Introduction*

10.00-13.00

1. MICROBIOLOGY I

Introduction: Basic and Clinical Microbiology for CF in Italy 2009 (**G. Döring**, Chairman) (10')

Bragonzi A

CFaCore: a core facility for animal model experiments in CF research (Project FFC CFaCore/2009) (10')

Bonomi F, Bertoni G

Dissecting a surface target candidate for the rational design of novel antibacterial drugs against Pseudomonas aeruginosa. (Project FFC#6/2007, concluded) (15')

Bertoni G, Maiorana S

Design of non-conventional antibiotics against cystic fibrosis-related pathogens (Project FFC#6/2008, in progress) (15')

Polissi A, Dehò G, De Castro C, Bolognesi M, Cipolla L, De Gioia L

Essential proteins of Pseudomonas aeruginosa outer membrane biogenesis as novel targets for new anti-microbial drugs design and synthesis. (Project FFC#10/2008, in progress) (15')

Leoni L, Visca P

Development and validation of a novel screening system for the identification of Pseudomonas aeruginosa virulence inhibitor (Project FFC#8/2008, in progress) (15')

Gennaro R, Di Bonaventura G, Fiscarelli E

Novel strategies for respiratory infection therapy in CF. Use of natural and designed antibacterial peptides (Project FFC#12/2009, new) (10')

Pini A

In vivo characterization of a novel branched antimicrobial peptide specific for Gram-negative bacteria. Efficacy in P. aeruginosa lung infection and pharmacological profile (Project FFC#14/2009, new) (10')

Molinaro A, Bernardini ML

Biochemical adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients (Project FFC#8/2007, concluded) (15')

Visca P, Leoni L

Iron uptake and quorum sensing in Pseudomonas aeruginosa virulence (Project FFC#10/2007, concluded) (15')

Landini P, Seneci P, Bernardi A, Cutruzzolà F

Prevention of Pseudomonas aeruginosa biofilm formation by inhibition of cyclic-di-GMP (c-di-GMP) metabolism (Project FFC#13/2009, new) (10')

Discussion after single or grouped presentations

Ore 13.00 -14.00 Lunch

14.00 – 17.00

2. CFTR PATHOPHYSIOLOGY AND THERAPY OF THE BASIC DEFECT

Introduction: Balance and perspectives in searching for therapy of the basic defect (A. Cao, Chairman) (10')

Casavola V, Conese M

- Cellular and molecular mechanisms of the actin cytoskeleton involvement in the NHERF1-dependent rescue of deltaF508 CFTR in human airway cells (Project FFC#2/2007, concluded)
- Interactome in Cystic Fibrosis: role of NHERF1 in actin cytoskeleton and tight junction pathophysiology (Project FFC#1/2009, extension) (20')

Luini A

Organisation and regulation of the secretory trafficking of the cystic fibrosis transmembrane conductance regulator CFTR and of its pathogenic mutant DF508-CFTR (Project FFC#1/2008, in progress) (15')

Pinna LA

- Assessing the implication of protein kinase CK2 in cystic fibrosis pathogenesis (Project FFC#4/2007, concluded)
- Signaling potential of the Δ 508 CFTR mutation: a new paradigm to explain nonchannelopathy related aspects of cystic fibrosis (Project FFC#4/2009, extension) (20')

Mazzei M, Melloni E, Moro S, Galiotta JL

Computational design, biochemical study, synthesis and screening of pharmacological chaperones as correctors of Δ F508-CFTR (Project FFC#3/2007, concluded) (15')

Vassalli M

Direct visualization of CFTR conformation by atomic force microscopy imaging (Project FFC#6/2009, new) (10')

Galiotta JL, Millo E, Mazzei M

Development of small molecules to correct the defective chloride transport in cystic fibrosis (Project FFC#2/2009, extension Project FFC#3/2006) (15')

Moran O, Zegarra O

Functional and structural basis of the molecular mechanism of CFTR potentiators (Project FFC#2/2008, in progress) (15')

Pedemonte N

Dissection by RNAi-mediated silencing of molecular mechanism leading to F508del-CFTR misprocessing (Project FFC#3/2009, new) (10')

Zegarra O

Strategies for the suppression of Na⁺ and fluid hyperabsorption in cystic fibrosis airway disease (Project FFC#7/2009, new) (10')

Sorio C, Melotti P, Buffelli MR

Functional evaluation of CFTR in blood leukocytes in human subjects as a new tool for diagnostic and clinical research applications (Project FFC#5/2009, new) (10')

Discussion after single or grouped presentations

17.00 -17.20 Coffee break

17.20 – 19.20

3. MICROBIOLOGY II

Braconzi A, Bertoni G

Validation of novel vaccine candidates of Pseudomonas aeruginosa (Project FFC#10/2009, new) (10')

Neri AS, Rossolini G

Longitudinal study of Pseudomonas aeruginosa resistance: selection and evolution of resistance mechanisms in relation to antibiotic treatment in cystic fibrosis patients (Project FFC#9/2008, concluded) (15')

Riccardi G

The role of RND transporters in Burkholderia cenocepacia life by microarray analysis (Project FFC#15/2009, new) (10')

Bevivino A, Ascenzioni F

Burkholderia cenocepacia pathogenicity: synergistic interactions with Pseudomonas aeruginosa and adaptation to CF host (Project FFC#7/2008, in progress) (15')

Silipo A, De Soyza A

In vitro and in vivo studies of novel antimicrobials targeting bacterial cytoskeleton and cell surface virulence markers in the treatment of Burkholderia cepacia complex infection (Project FFC#16/2009, new) (10')

Colonna B, Sanguinetti M, Nicoletti M, Casalino M, Fiscarelli E

Stenotrophomonas maltophilia, a multidrug resistant emergent pathogen associated to cystic fibrosis: a post genomic approach to identify new immunological and therapeutical targets (Project FFC#7/2007, concluded) (15')

Venturi V

Burkholderia cepacia complex: closing down on the major virulence factors (Project FFC #9/2007, concluded) (15')

Discussion after single or grouped presentations

20.45 Social dinner (Ristorante Accademia)

Saturday November 28

9.00-11.30 (Sala Grande Convegni)

4. INFLAMMATION I

Introduction: The excessive inflammatory response in CF airways (G. Berton, Chairman) (10')

Nicolis E, Bezzeri V, Cabrini G

QuantiGENE: a core facility for quantification of gene expression in CF research (Project FFC Quantigene/2008) (10')

Cabrini G, Gambari R, Pucci P

- A gene-targeted anti-inflammatory approach based on the Transcription Factor "decoy" strategy (Project FFC#13/2007, concluded)

- Mapping IL-8 gene transcription machinery in bronchial epithelial cells (Project FFC#18/2009, extension) (20')

Quaglia F, Carnuccio R

Novel particulate systems for the delivery of an oligonucleotide decoy to Nuclear Factor- κ B: a potential strategy for treating cystic fibrosis (Project FFC#5/2007, concluded) (15')

De Rose V, Hirsch E, Döring G

Genetic and pharmacological validation of PI3K γ as a drug-target for the treatment of airway inflammation in CF (Project FFC#20/2009, new) (10')

Romano M, Battistini L, Furnari ML

Mechanisms of inflammation resolution in cystic fibrosis (Project FFC#15/2007, concluded) (15')

Garlanda C, Bragonzi A

Infections in cystic fibrosis: role of the long pentraxin PTX3 in host resistance and as therapeutic agent (Project FFC#14/2008, in progress) (15')

Dehecchi MC, Gambari R

Anti-inflammatory effect of miglustat: sphingolipid ceramide metabolism as a therapeutic target for CF lung disease (Project FFC#12/2008, in progress) (15')

Discussion after single or grouped presentations

11.30 – 11.50 Coffee break

11.50 – 13.50 (Sala Grande Convegna)

5. INFLAMMATION II

Del Porto P, Ascenzioni F, Quattrucci S

- *Influence of CFTR mutations in bactericidal activity of human macrophages (Project FFC#14/2007, concluded)*
- *Mechanisms of bactericidal activity of human macrophages and the influence of CFTR mutations (Project FFC#21/2009, extension) (20')*

Leal T, Mauri P, Sorio C

Effects of azithromycin (AZM) on Pseudomonas aeruginosa-induced chronic lung inflammation in cystic fibrosis (Project FFC#15/2008, in progress) (15')

Galli F, Iuliano L, Schock CB, Goracci GF

Pre-clinical evaluation of new vitamin E-based anti-inflammatory agents in CF (Project FFC#13/2008, in progress) (15')

Battistoni A, Berlutti F

Effect of glutathione and lactoferrin on redox regulation, metal homeostasis and inflammatory responses of Cystic Fibrosis bronchial cells upon infection with Burkholderia cenocepacia (Project FFC#11/2008, in progress) (15')

Pompella A

Origin of lung fluid gamma-glutamyltransferase and its effects in modulation of antioxidant balance, inflammation and CF respiratory dysfunction (Project FFC#22/2009, new) (10')

Bernardini ML, Molinaro A, Allaoui A

Immune evasion strategies underlining the adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients (Project FFC#17/2009, new) (10')

Chanson M, Dehecchi MC

Role of CFTR-Connexin interaction on PGE2 signaling and inflammation: implication for cystic fibrosis (Project FFC#19/2009, new) (10')

Discussion after single or grouped presentations

Saturday November 28

9.00-11.00 (Aula Incontri – Anfiteatro)

6. GENETICS

Introduction: Studies on emerging aspects of CF genetics (M.C. Rosatelli, Chairman) (10')

Pagani F

- *Evaluation of disease causing mutations in CFTR co-transcriptional splicing units: diagnostic and therapeutic aspects. (Project FFC#20/2007, concluded)*
- *Molecular pathology of the pre-mRNA splicing machinery in cystic fibrosis: mechanistic aspects and therapeutic approaches (Project FFC#9/2009, extension) (20')*

Gasparini P, Cabrini G

- *Influence of genetic factors in the progression of lung disease in cystic fibrosis (CF) (Project FFC#3/2008, concluded)*
- *Influence of genetic factors in the progression of lung disease in cystic fibrosis (Project FFC#8/2009, extension) (20')*

Pucci P, Tomaiuolo R, Bombieri C

Search of novel regulatory elements in the promoter region of CFTR gene (Project FFC#4/2008, in progress) (15')

Castaldo G

Molecular analysis of genes encoding CFTR interactors of SLC26 family in CF patients (Project FFC#19/2007, concluded) (15')

Rosatelli MC

Feasibility of a screening program for the preconceptional identification of Cystic Fibrosis carriers in Sardinian population. (Project FFC#5/2008, in progress) (15')

Discussion after single or grouped presentations

11.00 -11.30 Coffee break

11.30 - 13.30

7. CLINICAL RESEARCH

Introduction: Current context of clinical research in CF (R. Buzzetti, Chairman)

Taccetti G, Cariani L

Early antibiotic treatment in Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols (Project FFC#17/2007, in progress) (15')

Campana S

Impact on clinical status of cystic fibrosis patients of persistent lung infections with community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and hospital acquired methicillin-resistant Staphylococcus aureus (HA-MRSA): a multicenter longitudinal study (Project FFC#11/2009, new) (10')

Dal Molin A, Braggion C, Furnari ML, Lucidi V, Rizzi E, Cialdella P

A prospective study about complications of totally implantable central venous access ports in people with CF (Project FFC#16/2008, in progress) (15')

Ranieri VM

Extracorporeal lung assist as bridge to lung transplantation for patients with cystic fibrosis (Project FFC#17/2008, in progress) (15')

Remuzzi G

Prevention of reperfusion injury in human lung transplantation for cystic fibrosis by targeting IL-8 activity

(Project FFC#24/2009, new) (10')

Guarino A, Braggion C, Pardo F, Morelli L

Modulation of intestinal and extraintestinal inflammation in infants with cystic fibrosis by early modification of intestinal microflora (Project FFC#23/2009, new) (10')

Discussion after single or grouped presentations

Project group meetings

Some meetings of small groups can be arranged during the convention time, also on Saturday 28th afternoon. They could be proposed and managed by participants themselves. They require an application to be sent to FFC Secretary by November 20th: some rooms will be available for this purpose.

Note organizzative

- È necessario per tutti i partecipanti inviare entro il 6 novembre (deadline prorogata) la scheda di adesione compilata in ogni dettaglio.
- I tempi assegnati a ciascun relatore sono di 15 minuti per i progetti conclusi o in corso: i relatori che hanno ricevuto nel 2009 un nuovo grant per progetti di continuazione includeranno qualche cenno del nuovo progetto nella stessa relazione di 20 minuti complessivi; 10 minuti sono riservati ai progetti nuovi non di continuazione avviati nel 2009. I moderatori possono aggregare per discussione unica anche più progetti di tematiche affini.
- Sono raccomandate presentazioni in Power Point: le slides devono essere chiare e semplici, di facile leggibilità e in numero ragionevolmente limitato. CD o pen-drive andranno consegnati al tecnico di sala almeno mezz'ora prima dell'inizio della sessione.
(Power Point presentations are recommended: slides must be clear and simply, easy to read and not too long. CD or USB keys with the Power Point presentation must be given to the computer technician at least 30 minutes before the beginning of the session).
- La lingua ufficiale parlata è l'italiano. Tuttavia i ricercatori stranieri che dovessero relazionare o intervenire in discussione possono farlo in inglese.
(Italian will be the official spoken language but, of course, English may be used by those foreign researchers who have to do a presentation or wish to participate in the discussion).
- La sede della Convention (Centro Marani, Ospedale di Borgo Trento) è raggiungibile in 5 minuti a piedi dall'Hotel Italia, in 20 minuti a piedi dagli hotel situati in centro città (ma vi sono anche parecchi autobus). La cena sociale, venerdì 27 novembre alle ore 20.45, si svolgerà al Ristorante Accademia (Via Scala, 10 – centro città)
- Il rimborso delle spese di viaggio (su presentazione di pezzi giustificative: biglietti aereo, treno, ricevute di agenzia) è riservato solo ai responsabili o coordinatori di progetti (conclusi nel 2009 o in corso o di recente assegnazione) e ai loro partners ufficiali, così come indicati nelle forms dei progetti approvati da FFC, e solo ai borsisti o contrattisti, dipendenti da FFC, attivi nei progetti presentati alla Convention attualmente o fino al 31 agosto 2009 nei progetti conclusi. Agli stessi ricercatori è riservata la cena sociale del 27 novembre, offerta da FFC. Sono esclusi dal rimborso spese altri collaboratori interni ed esterni. Per ottenere il rimborso spese è necessario inviare alla Fondazione, dopo la convention, la scheda di richiesta compilata: il documento è stato inviato agli interessati tramite e-mail, ma se ne può richiedere copia alla segreteria FFC (fondazione.ricercafc@azosp.vr.it; tel.: 045/8123438).
- L'iscrizione alla Convention è aperta anche a ricercatori non direttamente coinvolti nei progetti presentati: necessita comunque inviare la scheda di iscrizione entro il 6 novembre 2009.